Summary

Market Size & Trends

The Middle East and Africa biomarker-based immunoassays market size was estimated at USD 165.4 million in 2024 and is projected to reach USD 234.2 million by 2033, growing at a CAGR of 3.8% from 2025 to 2033. The market growth is fueled by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools. Increasing demand for personalized medicine has driven clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring. Countries like Saudi Arabia, the UAE, and South Africa are at the forefront, investing heavily in diagnostic infrastructure and adopting international best practices.

A key trend shaping the market is the growing collaboration between global diagnostic leaders and regional healthcare providers. For instance, in January 2025, Diatech Pharmacogenetics expanded its collaboration with Merck to extend access to RAS biomarker testing for colorectal cancer patients in MEA, underscoring the region’s rising focus on personalized cancer care. Such partnerships not only expand the availability of advanced biomarker assays but also accelerate technology transfer and capacity building across the region. This trend indicates that international companies view MEA as a critical growth frontier for precision diagnostics.

The MEA region offers untapped potential for biomarker-based immunoassays due to its expanding healthcare infrastructure and growing demand for precision medicine. Governments across Saudi Arabia, the UAE, and South Africa are investing heavily in advanced diagnostics to reduce dependence on overseas testing, which creates a strong opening for localized manufacturing and technology transfer. In addition, the rising prevalence of lifestyle-related diseases, combined with an increasing focus on early detection and personalized treatment, is driving adoption of biomarker assays in oncology, cardiology, and neurology. The growing emphasis on value-based care also positions biomarker testing as a cost-efficient solution, supporting earlier interventions and better patient outcomes.

Strategic collaborations are playing a critical role in shaping the MEA biomarker ecosystem. In 2025, Diatech Pharmacogenetics expanded its partnership with Merck to improve colorectal cancer care in the region through RAS biomarker testing, highlighting the momentum in companion diagnostics. Similarly, partnerships between diagnostic technology providers like IBL International and Grifols are advancing biomarker panels that could see uptake in MEA’s expanding clinical research networks. Meanwhile, local institutions, such as King Faisal Specialist Hospital in Saudi Arabia, are launching advanced biomarker testing programs that integrate with global standards, underscoring the region’s commitment to becoming a hub for innovation in precision diagnostics.

MEA Biomarker-based Immunoassays Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East & Africa biomarker-based immunoassays market report based on the sample, product, biomarkers, diseases, end-use, and country.

• Sample Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Tissue
• Urine
• Saliva
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Consumables
• Instruments/Analyzers
• Reagent & Kits
• Services
• Biomarker Outlook (Revenue, USD Million, 2021 - 2033)
• Safety & toxicity biomarkers
• Efficacy & Pharmacodynamic Biomarkers
• Predictive & Prognostic Biomarkers
• Surrogate/Exploratory Biomarkers
• Diseases Outlook (Revenue, USD Million, 2021 - 2033)
• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Sample Segment
1.2.2. Product Segment
1.2.3. Biomarker Segment
1.2.4. Diseases Segment
1.2.5. End-use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Biomarkerl
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. MEA Biomarker-Based Immunoassays Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising demand for precision medicine and personalized therapies
3.2.1.2. Increasing prevalence of chronic and infectious diseases
3.2.1.3. Technological advancements in immunoassay platforms
3.2.2. Market restraint analysis
3.2.2.1. High cost of advanced biomarker assays and platforms
3.3. MEA Biomarker-Based Immunoassays Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. MEA Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. MEA Biomarker-Based Immunoassays Market Sample Movement Analysis
4.3. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2030 (USD Million)
4.4. Blood
4.4.1. Blood market estimates and forecasts, 2021 to 2033 (USD Million)
4.5. Tissue
4.5.1. Tissue market estimates and forecasts, 2021 to 2033 (USD Million)
4.6. Saliva
4.6.1. Saliva market estimates and forecasts, 2021 to 2033 (USD Million)
4.7. Urine
4.7.1. Urine market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. MEA Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. MEA Biomarker-Based Immunoassays Market Product Movement Analysis
5.3. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
5.4. Consumables
5.4.1. Consumables market estimates and forecasts, 2021 to 2033 (USD Million)
5.5. Instruments/Analyzers
5.5.1. Instruments/Analyzers market estimates and forecasts, 2021 to 2033 (USD Million)
5.6. Reagent & Kits
5.6.1. Reagent & kits market estimates and forecasts, 2021 to 2033 (USD Million)
5.7. Services
5.7.1. Services market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. MEA Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. MEA Biomarker-Based Immunoassays Market Biomarker Movement Analysis
6.3. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
6.4. Safety & toxicity biomarkers
6.4.1. Safety & toxicity biomarkers market estimates and forecasts, 2021 to 2033 (USD Million)
6.5. Efficacy & Pharmacodynamic Biomarkers
6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts, 2021 to 2033 (USD Million)
6.6. Predictive & Prognostic Biomarkers
6.6.1. Predictive & prognostic biomarkers market estimates and forecasts, 2021 to 2033 (USD Million)
6.7. Surrogate/Exploratory Biomarkers
6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. MEA Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. MEA Biomarker-Based Immunoassays Market Diseases Movement Analysis
7.2.1. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
7.3. Cancer
7.3.1. Cancer market estimates and forecasts, 2021 to 2033 (USD Million)
7.4. Cardiovascular Diseases
7.4.1. Cardiovascular diseases market estimates and forecasts, 2021 to 2033 (USD Million)
7.5. Neurological Diseases
7.5.1. Neurological diseases market estimates and forecasts, 2021 to 2033 (USD Million)
7.6. Immunological Diseases
7.6.1. Immunological diseases testing market estimates and forecasts, 2021 to 2033 (USD Million)
7.7. Others
7.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 8. MEA Biomarker-Based Immunoassays Market: End-use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. MEA Biomarker-Based Immunoassays Market End-use Movement Analysis
8.2.1. MEA Biomarker-Based Immunoassays Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
8.3. Hospitals & Clinics
8.3.1. Hospitals and clinics market estimates and forecasts, 2021 to 2033 (USD Million)
8.4. Diagnostic Laboratories
8.4.1. Diagnostic Laboratories market estimates and forecasts, 2021 to 2033 (USD Million)
8.5. Research & Academic Institutes
8.5.1. Research & Academic Institutes market estimates and forecasts, 2021 to 2033 (USD Million)
8.6. Others
8.6.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 9. MEA Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis
9.1. Regional Dashboard
9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033
9.3. MEA
9.3.1. South Africa
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework/ reimbursement structure
9.3.1.3. Competitive scenario
9.3.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
9.3.2. Saudi Arabia
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework/ reimbursement structure
9.3.2.3. Competitive scenario
9.3.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
9.3.3. UAE
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework/ reimbursement structure
9.3.3.3. Competitive scenario
9.3.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
9.3.4. Kuwait
9.3.4.1. Key country dynamics
9.3.4.2. Regulatory framework/ reimbursement structure
9.3.4.3. Competitive scenario
9.3.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company/Competition Categorization
10.2. Strategy Mapping
10.3. Company Market Share Analysis, 2024
10.4. List of Key Certification Providers/Scheme Owners
10.5. Company Profiles/Listing
10.5.1. F. Hoffmann-La Roche AG
10.5.1.1. Company overview
10.5.1.2. Financial performance
10.5.1.3. Product benchmarking
10.5.1.4. Strategic initiatives
10.5.2. Abbott
10.5.2.1. Company overview
10.5.2.2. Financial performance
10.5.2.3. Product benchmarking
10.5.2.4. Strategic initiatives
10.5.3. Thermo Fisher Scientific Inc
10.5.3.1. Company overview
10.5.3.2. Financial performance
10.5.3.3. Product benchmarking
10.5.3.4. Strategic initiatives
10.5.4. Eurofins Scientific
10.5.4.1. Company overview
10.5.4.2. Financial performance
10.5.4.3. Product benchmarking
10.5.4.4. Strategic initiatives
10.5.5. QIAGEN
10.5.5.1. Company overview
10.5.5.2. Financial performance
10.5.5.3. Product benchmarking
10.5.5.4. Strategic initiatives
10.5.6. Bio-Rad Laboratories, Inc.
10.5.6.1. Company overview
10.5.6.2. Financial performance
10.5.6.3. Product benchmarking
10.5.6.4. Strategic initiatives
10.5.7. Siemens Healthineers AG
10.5.7.1. Company overview
10.5.7.2. Financial performance
10.5.7.3. Product benchmarking
10.5.7.4. Strategic initiatives
10.5.8. Merck KGaA
10.5.8.1. Company overview
10.5.8.2. Financial performance
10.5.8.3. Product benchmarking
10.5.8.4. Strategic initiatives
10.5.9. PerkinElmer Inc.
10.5.9.1. Company overview
10.5.9.2. Financial performance
10.5.9.3. Product benchmarking
10.5.9.4. Strategic initiatives
10.5.10. Agilent Technologies, Inc.
10.5.10.1. Company overview
10.5.10.2. Financial performance
10.5.10.3. Product benchmarking
10.5.10.4. Strategic initiatives